| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911115 | Lung Cancer | 2014 | 5 Pages |
Abstract
Hyponatremia is an independent prognostic factor for patients with SCLC treated with topotecan in second-line setting. Further studies are needed to prospectically confirm these results and to develop an optimal therapy for hyponatremic patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marcello Tiseo, Sebastiano Buti, Luca Boni, Roberto Mattioni, Andrea Ardizzoni,